Breakthrough: New Drug Shows Promise in Treating Long COVID Fatigue

Durham, Monday, 18 November 2024.
In a significant medical advancement, Dogwood Therapeutics’ low-dose IMC-2 treatment demonstrates effectiveness against long COVID fatigue and sleep disorders. The treatment combines valacyclovir and celecoxib, offering hope to millions of long COVID sufferers who currently have no FDA-approved treatment options. This development is particularly crucial as over 50% of COVID-19 survivors report persistent fatigue months after recovery.